Effect of Glucocorticoids on Osteoclast Function in a Mouse Model of Bone Necrosis

Overview

Journal Mol Med Rep

Specialty Molecular Biology

Date 2016 Jun 10

PMID 27277157

Citations 10

Authors

Ming He

Jiashi Wang

Guangbin Wang

Ye Tian

Linlin Jiang

Zhaozhou Ren

Chuang Qiu

Qin Fu

Affiliations

Soon will be listed here.

Abstract

Osteonecrosis, also termed aseptic necrosis, is the cellular death of bone components due to interruption of the blood supply. Glucocorticoid (GC) therapy is a common non-traumatic cause of osteonecrosis. However, the mechanism by which GCs induce osteonecrosis remains to be elucidated. The aim of the present study was to investigate the effects of GCs on osteoclast and osteoblast differentiation and function in a GC‑induced osteonecrosis mouse model. BALB/c male mice (n=40; 4‑weeks‑old) were treated with dexamethasone and asparaginase for 8 weeks. The control group (n=20) was administered normal saline. The results demonstrated that the GC-treated group had a lower mean weight compared with the control group. Morphologically, 16/37 (43%) mice demonstrated significant osteonecrotic lesions in the GC‑treated group. However, osteonecrotic lesions were not observed in the mice of the control group. Furthermore, immunohistochemistry demonstrated that the GC‑treated group had a higher level of osteoprotegerin compared with the control group, without any change in the expression of receptor activator of nuclear factor‑κB ligand. In addition, tartarate‑resistant acid-phosphatase staining demonstrated significantly decreased osteoclasts in the areas of bone destruction in the GCs-treated group. Furthermore, the present study demonstrated that GCs increased expression levels of osterix and osteocalcin, and decreased expression of matrix metallopeptidase‑9 to regulate the differentiation and function of osteoblasts and osteoclasts. The results of the present study suggested that GCs influence bone remolding resulting in decreased osteoclasts formation/differentiation. Therefore, regulating the differentiation and activity of the osteoclasts may be beneficial to the control and treatment of osteonecrosis.

Citing Articles

High cumulative glucocorticoid dose is associated with increased levels of inflammation-related mediators in active rheumatoid arthritis.

Petrackova A, Horak P, Savara J, Skacelova M, Kriegova E Front Immunol. 2025; 15:1505615.

PMID: 39744635 PMC: 11688219. DOI: 10.3389/fimmu.2024.1505615.

Changes in Angiogenesis and Bone Turnover Markers in Patients with Gaucher Disease Developing Osteonecrosis.

DAmore S, Poole K, Ramaswami U, Hughes D, Page K, Solimando A Metabolites. 2024; 14(11).

PMID: 39590837 PMC: 11596658. DOI: 10.3390/metabo14110601.

Phase-contrast imaging with synchrotron hard X-ray reveals the effect of icariin on bone tissue morphology and microstructure in rabbits with early glucocorticoid-induced osteonecrosis of the femoral head.

Yang X, Shi L, Li A, Gao F, Sun W, Li Z Front Cell Dev Biol. 2023; 11:1155532.

PMID: 37215078 PMC: 10192577. DOI: 10.3389/fcell.2023.1155532.

Effects of angiotensin II combined with asparaginase and dexamethasone on the femoral head in mice: A model of steroid-induced femoral head osteonecrosis.

Liu J, Li C, Yang F, Li M, Wu B, Chen H Front Cell Dev Biol. 2022; 10:975879.

PMID: 36187471 PMC: 9521711. DOI: 10.3389/fcell.2022.975879.

Vitamin D Auto-/Paracrine System Is Involved in Modulation of Glucocorticoid-Induced Changes in Angiogenesis/Bone Remodeling Coupling.

Lisakovska O, Shymanskyi I, Labudzynskyi D, Mazanova A, Veliky M Int J Endocrinol. 2020; 2020:8237610.

PMID: 32952554 PMC: 7487101. DOI: 10.1155/2020/8237610.

References

Lafforgue P . Pathophysiology and natural history of avascular necrosis of bone. Joint Bone Spine. 2006; 73(5):500-7. DOI: 10.1016/j.jbspin.2006.01.025. View

Yamada Y, Ando F, Niino N, Shimokata H . Association of polymorphisms of the osteoprotegerin gene with bone mineral density in Japanese women but not men. Mol Genet Metab. 2003; 80(3):344-9. DOI: 10.1016/S1096-7192(03)00125-2. View

Tingart M, Beckmann J, Opolka A, Matsuura M, Wiech O, Grifka J . Influence of factors regulating bone formation and remodeling on bone quality in osteonecrosis of the femoral head. Calcif Tissue Int. 2008; 82(4):300-8. DOI: 10.1007/s00223-008-9111-z. View

Lian J, Stein G . Runx2/Cbfa1: a multifunctional regulator of bone formation. Curr Pharm Des. 2003; 9(32):2677-85. DOI: 10.2174/1381612033453659. View

Yamamoto T, Hirano K, Tsutsui H, Sugioka Y, Sueishi K . Corticosteroid enhances the experimental induction of osteonecrosis in rabbits with Shwartzman reaction. Clin Orthop Relat Res. 1995; (316):235-43. View

Levasseur R . Mechanisms of osteonecrosis. Joint Bone Spine. 2008; 75(6):639-42. DOI: 10.1016/j.jbspin.2008.10.001. View

Teitelbaum S . Bone resorption by osteoclasts. Science. 2000; 289(5484):1504-8. DOI: 10.1126/science.289.5484.1504. View

Blair J, Zheng Y, Dunstan C . RANK ligand. Int J Biochem Cell Biol. 2006; 39(6):1077-81. DOI: 10.1016/j.biocel.2006.11.008. View

Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K . Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997; 89(5):755-64. DOI: 10.1016/s0092-8674(00)80258-5. View

10.

Marti-Carvajal A, Dunlop R, Agreda-Perez L . Treatment for avascular necrosis of bone in people with sickle cell disease. Cochrane Database Syst Rev. 2004; (4):CD004344. DOI: 10.1002/14651858.CD004344.pub2. View

11.

Dannemann C, Gratz K, Riener M, Zwahlen R . Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder. Bone. 2007; 40(4):828-34. DOI: 10.1016/j.bone.2006.11.023. View

12.

Lee N, Sowa H, Hinoi E, Ferron M, Ahn J, Confavreux C . Endocrine regulation of energy metabolism by the skeleton. Cell. 2007; 130(3):456-69. PMC: 2013746. DOI: 10.1016/j.cell.2007.05.047. View

13.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

14.

DiGiovanni C, Patel A, Calfee R, Nickisch F . Osteonecrosis in the foot. J Am Acad Orthop Surg. 2007; 15(4):208-17. DOI: 10.5435/00124635-200704000-00004. View

15.

Wyles C, Houdek M, Crespo-Diaz R, Norambuena G, Stalboerger P, Terzic A . Adipose-derived Mesenchymal Stem Cells Are Phenotypically Superior for Regeneration in the Setting of Osteonecrosis of the Femoral Head. Clin Orthop Relat Res. 2015; 473(10):3080-90. PMC: 4562944. DOI: 10.1007/s11999-015-4385-8. View

16.

Baksi D . Treatment of post-traumatic avascular necrosis of the femoral head by multiple drilling and muscle-pedicle bone grafting. Preliminary report. J Bone Joint Surg Br. 1983; 65(3):268-73. DOI: 10.1302/0301-620X.65B3.6341373. View

17.

Weinstein R, Jilka R, Parfitt A, Manolagas S . Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998; 102(2):274-82. PMC: 508885. DOI: 10.1172/JCI2799. View

18.

Harada S, Rodan G . Control of osteoblast function and regulation of bone mass. Nature. 2003; 423(6937):349-55. DOI: 10.1038/nature01660. View

19.

Powell C, Chang C, Gershwin M . Current concepts on the pathogenesis and natural history of steroid-induced osteonecrosis. Clin Rev Allergy Immunol. 2010; 41(1):102-13. DOI: 10.1007/s12016-010-8217-z. View

20.

Galindo M, Pratap J, Young D, Hovhannisyan H, Im H, Choi J . The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J Biol Chem. 2005; 280(21):20274-85. PMC: 2895256. DOI: 10.1074/jbc.M413665200. View